Caisse DE Depot ET Placement DU Quebec Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Caisse DE Depot ET Placement DU Quebec lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 151.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,927 shares of the company’s stock after purchasing an additional 51,728 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in IDEXX Laboratories were worth $43,412,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Atria Investments Inc increased its holdings in shares of IDEXX Laboratories by 11.5% in the 1st quarter. Atria Investments Inc now owns 4,549 shares of the company’s stock worth $2,456,000 after buying an additional 470 shares during the last quarter. Cetera Investment Advisers raised its position in IDEXX Laboratories by 294.8% during the first quarter. Cetera Investment Advisers now owns 20,129 shares of the company’s stock valued at $10,868,000 after purchasing an additional 15,030 shares in the last quarter. GAMMA Investing LLC lifted its stake in IDEXX Laboratories by 96.6% during the second quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock worth $570,000 after purchasing an additional 575 shares during the last quarter. Mather Group LLC. boosted its holdings in shares of IDEXX Laboratories by 4.2% in the 2nd quarter. Mather Group LLC. now owns 594 shares of the company’s stock worth $321,000 after purchasing an additional 24 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in shares of IDEXX Laboratories by 11.2% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 917 shares of the company’s stock valued at $447,000 after purchasing an additional 92 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $421.75 on Monday. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The firm has a market cap of $34.54 billion, a P/E ratio of 40.67, a P/E/G ratio of 3.68 and a beta of 1.36. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a 50-day moving average of $451.91 and a 200-day moving average of $477.31.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter last year, the business posted $2.53 EPS. The business’s revenue was up 6.6% on a year-over-year basis. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IDXX. Barclays dropped their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Piper Sandler reiterated a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $552.38.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.